Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response

Vaccine

Volumn 21, Issue 11-12, 2003, Pages 1174-1179

  Kim, Myong Jin ^a   Nafziger, Anne N ^a,b   Harro, Clayton D ^c   Keyserling, Harry L ^d   Ramsey, Keith M ^e   Drusano, George L ^f   Bertino Jr , Joseph S ^a,b  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b Johns Hopkins University ^*  (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^f ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Granulocyte macrophage colony stimulating factor; Hepatitis B virus vaccine; Revaccination

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B VACCINE; MEMBRANE ANTIGEN;

ADULT; ARTICLE; BODY HEIGHT; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG MEGADOSE; FEMALE; HEALTH STATUS; HUMAN; IMMUNE RESPONSE; MALE; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; PROTECTION; REVACCINATION; TIME;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; VACCINES, SYNTHETIC;

EID: 0037424116     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00626-6     Document Type: Article

References (31)

1. Roome A., Walsh S., Cartter M.et al. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA. 270:1993;2931-2934.
2. Rumi M., Colombo M., Romeo R.et al. Suboptimal response to hepatitis B vaccine in drug users. Arch. Intern. Med. 151:1991;574-578.
3. Trivello R., Chiaramonte M., Ngatchu T.et al. Persistence of anti-HBs antibodies in health care personnel vaccinated with plasma-derived hepatitis B vaccine and response to recombinant DNA HB booster vaccine. Vaccine. 13:1995;139-141.
4. Cardell K., Fryden A., Normann B. Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practice. Scand. J. Infect. Dis. 31:1999;197-200.
5. Hollinger F.B. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am. J. Med. 87(Suppl 3A):1989;36S-40S.
6. Horowitz M.M., Ershler W.B., McKinney W.P.et al. Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine. Ann. Intern. Med. 108:1988;185-189.
7. Wood R.C., MacDonald K.L., White K.E.et al. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA. 270:1993;2935-2939.
8. Alimonos K., Nafziger A.N., Murray J.et al. Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness? Clin. Infect. Dis. 26:1998;566-571.
9. Weber D.J., Rutala W.A., Samsa G.P.et al. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA. 254:1985;3187-3189.
10. Craven D.E., Awdeh Z.L., Kunches L.M.et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Ann. Intern. Med. 105:1986;356-360.
11. McCombs C.C., Leggett A., Ramsey K.M.et al. The association of HLA class II alleles defined by restriction fragment length polymorphisms with responsiveness to hepatitis B vaccine. Vaccine Res. 2:1993;105-109.
12. McLean A.A., Guess H.A., Scolnick E.M. Suboptimal response to hepatitis B vaccine given by injection into the buttock. MMWR. 34:1985;105-108.
13. Bock H.L., Kruppenbacker J., Sanger R.et al. Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch. Intern. Med. 156:1996;2226-2231.
14. 2 particles for revaccination of healthy adult nonresponders. J. Infect. Dis. 175:1997;678-681.
15. Goldwater P.N. Randomized, comparative trial of 20 vs. 40 μg Engerix-B vaccine in hepatitis B vaccine nonresponders. Vaccine. 15:1997;353-356.
16. Nagafuchi S., Kashiwagi S., Okada K.et al. Reversal of nonresponders and postexposure prophylaxis by intradermal hepatitis B vaccination in Japanese medical personnel. JAMA. 265:1991;2679-2683.
17. Lin R., Tarr P.E., Jones T.C.et al. Present status of the use of cytokines as adjuvants with vaccines to protect against infectious disease. Clin. Infect. Dis. 21:1995;1439-1449.
18. Taglietti M. Vaccine adjuvancy: a new potential area of development for GM-CSF. Adv. Exp. Med. Biol. 378:1995;565-569.
19. National Center for Health Statistics. Obese and overweight adults in the United States. Bethesda (ML): US Department of Health and Human Services; 1983. p. 1-3 [Series 11, no. 320].
20. Struve J., Aronsson B., Frenning B.et al. Seroconversion after additional doses to nonresponders to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine. Scand. J. Infect. Dis. 26:1994;468-470.
21. Gupta R.K., Relyveld E.H., Lindblad E.B.et al. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine. 11:1993;293-306.
22. Jones T., Stern A., Lin R. Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant. Eur. J. Clin. Microbiol. Infect. Dis. 13(Suppl 2):1994;S47-S53.
23. Steinman R. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:1991;271-296.
24. Liehl E., Hildebrandt J., Lam C.et al. Prediction of the role of granulocyte-macrophage colony-stimulating factor in animals and man frim in vitro results. Eur. J. Clin. Microbiol. Infect. Dis. 13(Suppl 2):1994;S9-S17.
25. Tarr P.E., Lin R., Mueller E.A.et al. Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. Vaccine. 14:1996;1199-1204.
26. Taglietti M, Rouzier-Panis R, Aymard M, et al. A double-blind placebo-controlled study to assess the immune response to influenza vaccine following a single dose of Rh GM-CSF in elderly people. In: Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 8-13 August 1994, Orlando, FL. Washington (DC): American Society for Microbiology; 1994. p. 266.
27. Carlsson T., Struve J. Granulocyte-macrophage colony-stimulating factor given as an adjuvant to persons not responding to hepatitis B vaccine. Infection. 25:1997;129.
28. Kapoor D., Aggarwal S.R., Singh N.P.et al. Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus in previously unvaccinated haemodialysis patients. J. Viral Hepat. 6:1999;405-409.
29. Anandh U., Bastani B., Ballal S. Granulocyte-macrophage colony-stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients. Am. J. Nephrol. 20:2000;53-56.
30. Evans T.G., Schiff M., Graves B.et al. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin. Nephrol. 54:2000;138-142.
31. Hess G., Kreiter F., Kosters W.et al. The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients. J. Viral Hepat. 3:1996;149-153.